BS PHARM KOREA’s INHILO+ market development has gained international media attention, highlighting the company’s ongoing clinical evaluation, domestic distribution, and global expansion activities.

Published in September 2026, the article highlights BS PHARM KOREA’s approach to building the market foundation for INHILO+ through clinical evaluation, domestic distribution, and international market development.

It also introduces the company’s efforts to strengthen professional collaboration and expand communication with global partners.

▶ INHILO+ Market Development Through Clinical and Distribution Collaboration

The international media coverage highlights several milestones supporting the continued development of INHILO+.

These include existing clinical data, an ongoing clinical evaluation program in South Korea, and a domestic distribution partnership with Dongkook Pharmaceutical.

Together, these activities support the continued market development of INHILO+ and strengthen evidence-based communication with professional partners. The company combines differentiated formulation concepts with clinical evaluation, professional collaboration, and established distribution partnerships.

▶ INHILO+: A Dual-Molecular HA Skin Booster

INHILO+ is formulated with 48 mg of cross-linked hyaluronic acid in a 2 mL syringe.

The formulation combines 24 mg of high molecular weight HA and 24 mg of low molecular weight HA in a single product.

This Dual-Molecular HA concept was developed around a skin quality-focused approach. It is also one of the key formulation features highlighted in the international media article.

For more detailed product information, visitors can explore the dedicated INHILO+ product page on the BS PHARM KOREA website.

▶ Supporting Product Development with Clinical Data

Clinical evaluation plays an important role in the market development of INHILO+.

The international media article introduces existing clinical data from a manufacturer-sponsored study involving 55 subjects. The study evaluated wrinkle improvement and overall aesthetic enhancement through participant self-assessments at several follow-up points.

In addition, BS PHARM KOREA is conducting a further clinical evaluation in collaboration with medical professionals in South Korea.

The ongoing program uses standardized treatment and follow-up conditions to generate additional clinical insights related to skin quality and participant outcomes.

This process supports continued evidence-based communication around INHILO+ and its professional aesthetic positioning.

▶ Domestic Distribution with Dongkook Pharmaceutical

In February 2026, BS PHARM KOREA established a domestic distribution partnership with Dongkook Pharmaceutical for INHILO+.

The collaboration supports wider market access within Korea and strengthens the product’s domestic commercial foundation.

It also represents an important milestone in the broader market development strategy for INHILO+.

For more information, visitors can read the dedicated update on the INHILO+ domestic distribution partnership.

▶ Expanding Global Communication and Market Presence

The international media publication forms part of BS PHARM KOREA’s broader global communication strategy.

By sharing clinical, distribution, and market development updates through international media, BS PHARM KOREA aims to improve transparency and provide global partners with clearer business and product information.

Beyond media coverage, BS PHARM KOREA continues to introduce INHILO+ through international exhibitions and industry events.

Going forward, BS PHARM KOREA plans to continue sharing updates on clinical collaboration, product development, and global market expansion.

▶ Read the Full International Media Article

The full article covers the formulation, clinical data, domestic distribution partnership, ongoing clinical evaluation, and international market development of INHILO+.

Article Title:
BS PHARM KOREA Strengthens INHILO+ Market Development Through Distribution and Clinical Collaboration